Interferon News and Research

RSS

Serono says Rebif an effective treatment for brain lesions

New long-term data support the importance of early treatment with high dose, high frequency Rebif® (interferon beta-1a) 44 mcg in reducing the long-term accumulation of brain lesion volume in patients with relapsing remitting multiple sclerosis (MS).

28 Apr 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004

Oral treatment of chronic hepatitis C

Valeant Pharmaceuticals today presented 24-week data from Phase 2 clinical trials of Viramidine, a nucleoside (guanosine) analog Valeant is developing in oral form for the treatment of chronic hepatitis C (HCV) in conjunction with a pegylated interferon.

17 Apr 2004

New diagnostic test for latent tuberculosis introduced

The Tuberculin skin test, used to detect latent Mycobacterium tuberculosis infection, has many drawbacks and a new diagnostic test for latent tuberculosis (QuantiFERON®-TB) has recently been introduced.

17 Apr 2004

Daycare and siblings increase likelihood of contracting respiratory syncytial virus and rhinovirus

Daycare attendance and siblings are associated with viral-induced wheezing in children. Pre-existing immunologic factors may influence the expression of viral infections in infancy, and in turn, recurrent infections may influence the development of immune responses.

17 Apr 2004

New insights into how tumors neutralize CD8 T cells

Scientists have speculated that this may be because the immune response is not strong enough, or because it does not last long enough to have an effect. Hence the increasing efforts to develop cancer vaccines that induce, strengthen, and increase the duration of immunological attack against cancer cells.

16 Apr 2004

Launch of thin needle syringe for multiple sclerosis treatment

A study conducted in Denmark showed that 86% of Rebif®-treated patients found that injections were easier and less painful using the new needle. The pre-filled syringe of Rebif® with the new needle is available in the same dosages as the previous version and will continue to carry the same indication. It is currently being launched in Europe and will be available worldwide by the end of 2004.

31 Mar 2004

Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors

Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research demonstrated highlighted how some drugs may one day offer previously unforeseen benefits for patients.

30 Mar 2004

Haemophilia Society President presents Hepatitis C (HCV) Facts to UK Government

Haemophilia Society President to challenge government for second time in Lords question on proposed Hepatitis C ex gratia payment scheme On Thursday 25 March, the first business in the House of Lords will be further questioning of Ministers by the Haemophilia Society’s President, Lord Morris of Manchester.

27 Mar 2004